Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANV 419

Next Previous
X
Search
Drug Profile

ANV 419

Alternative Names: ANV-419

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anaveon
  • Class Adjuvants; Antibodies; Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Solid tumours
  • Phase I Multiple myeloma

Most Recent Events

  • 20 Oct 2023 Safety, efficacy and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 09 Aug 2023 Anaveon AG terminates a phase I OMNIA-2 trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Denmark, France, Germany, Spain and Switzerland (IV) due to a lack of recruitment (NCT05641324)
  • 21 Jun 2023 Anaveon AG in collaboration with University Hospital initiates the phase I BaseTIL-03M trial for Malignant melanoma (Combination therapy, Late-stage disease, Second-line therapy) in Switzerland (IV) (NCT05869539)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top